Study Graphic

Study number: B4541023

You may be eligible if:

  • You are a healthy male or female 18-55 years of age.
  • You are able to meet all eligibility criteria.
  • You are able to comply with all study visits.

Be compensated for your time: You will be paid will be up to $3,400.00 for completion of the study.

 The Pfizer New Haven Clinical Research Unit is conducting a study of a marketed drug approved by the Food and Drug Administration (FDA) for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. It is approved for adults only when other treatments are not adequate.  Study drug will be given orally (by mouth) as a capsule to be swallowed whole.

This study involves:

You will be in this study up to about 44 days. This does not include the time between screening and dosing, which can be up to 28 days.

 This study involves:

  • 2 dosing periods (during one continuous admission)
  • 12 overnight stays
  • 1 follow-up phone call (between 28 and 35 days after the last dose of study drug)There will be at least 7 days between each dose.

Please review the Informed Consent Document: B4541023 change in PI ICD v.11Jan2019

Please review more information about the study: B4541023 revised Guidelines v11Dec2018